Farnesyl Protein Transferase Inhibition: A Novel Approach to Anti-tumor

Author(s): A. K. Ganguly, R. J. Doll, V.M. Girijavallabhan

Journal Name: Current Medicinal Chemistry

Volume 8 , Issue 12 , 2001

Become EABM
Become Reviewer
Call for Editor


Farnesyl protein transferase (FPT) inhibition is an interesting and promising approach to non-cytotoxic anticancer therapy. Research in this area has resulted in several orally active compounds that are currently in clinical evaluation. This review focuses on FPT inhibitors in clinical trials and concentrates on the benzocycloheptapyridine class, with details on the discovery and development of SCH 66336, currently in Phase II clinical trials.

Keywords: Farnesyl Protein Transferase Inhibition, Anti-tumor Therapy, farnesyl protein transferase, Farnesylation, Geranlylgeranylation, carboxymethyl transferase, FPT Enzyme Assay, COS Assay, Pharmacokinetic Assay (PK), Potent FPT Inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2001
Page: [1419 - 1436]
Pages: 18
DOI: 10.2174/0929867013372021
Price: $65

Article Metrics

PDF: 1